Crossmark

A group sequential response-adaptive randomized double-blinded clinical trial to evaluate the safety and efficacy of add-on olanzapine plus pregabalin for the prevention of chemotherapy-induced nausea and vomiting

Crossref DOI link: https://doi.org/10.1007/s00520-025-09275-2

Published Online: 2025-02-19

Published Print: 2025-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ramasubbu, Mathan Kumar

Hota, Debasish

Das Majumdar, Saroj kumar

Parida, Dillip Kumar

Mukherjee, Priyanka

Srinivasan, Anand
Funding

Funding for this research was provided by:

Indian Council of Medical Research (No. 3/2/June- 2021/Pg-Thesis-HRD (01))
License Information

Text and Data Mining valid from 2025-02-19

Version of Record valid from 2025-02-19
More Information

Article History

Received: 19 September 2023

Accepted: 13 February 2025

First Online: 19 February 2025

Declarations

:

: The Institutional Ethics Committee of All India Institute of Medical Sciences, Bhubaneswar, approved the trial protocol. Written informed consent was obtained from all the participants. The trial was conducted in accordance with “Declaration of Helsinki” and “National Ethical Guidelines for Biomedical and Health Research involving Human Participants (2017)” by the Indian Council of Medical Research.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below